Omnicell Inc. Stock
Omnicell Inc. Stock
We can see a decrease in the price for Omnicell Inc.. Compared to yesterday it has lost -€0.400 (-1.320%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Omnicell Inc..
With a target price of 37 € there is a positive potential of 24.16% for Omnicell Inc. compared to the current price of 29.8 €.
Pros and Cons of Omnicell Inc. in the next few years
Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omnicell Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omnicell Inc. | -1.320% | -14.607% | -0.654% | 2.703% | -21.649% | -37.449% | -72.364% |
| Healthequity Inc. | 2.270% | 0.000% | 7.258% | -22.222% | -14.744% | 14.655% | 3.101% |
| Bruker Corp. | -3.260% | -6.487% | -3.871% | -28.726% | -27.556% | - | - |
| Myriad Genetics | -2.880% | -5.455% | 11.230% | -54.033% | -21.509% | -79.111% | -83.895% |
Comments
Omnicell (NASDAQ:OMCL) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $70.00 price target on the stock.
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for OMCL provided by MarketBeat
Omnicell (NASDAQ:OMCL) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Show more
Ratings data for OMCL provided by MarketBeat
News
Omnicell Executive Trims Holdings in $244,000 Sale as Stock Trades Near 2025 Highs
Corey J Manley, EVP & Chief Legal/Admin Officer at Omnicell (NASDAQ:OMCL), executed an open-market sale of 6,106 shares for $243,629.40 on Dec. 3, 2025, as reported in the SEC Form 4 filing.
Why Omnicell Stock Crushed the Market Today
Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares